Fri March 13, 2020 7:00 AM|GlobeNewswire|About: GWPH
LONDON, March 13, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (GWPRF) (Nasdaq: GWPH)
https://ghr.nlm.nih.gov/condition/tuberous-sclerosis-complex
https://seekingalpha.com/symbol/GWPH
Fri March 13, 2020 7:00 AM|Business Wire|About: ENTA
Company Leverages Proven Antiviral and Respiratory Expertise to Evaluate Existing Compounds and New Approaches for Treating the Novel Coronavirus Disease COVID-19
WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (ENTA)
https://www.enanta.com/home/default.aspx
Fri March 13, 2020 10:09 PM|PR Newswire|About: TMO
WALTHAM, Mass., March 13, 2020 /PRNewswire/ -- Thermo Fisher Scientific Inc. (TMO)
https://www.thermofisher.com/us/en/home.html
FDA Issues Emergency Use Authorization to Thermo Fisher Scientific for Diagnostic Test Used to Detect COVID-19
https://seekingalpha.com/symbol/TMO
Mon March 16, 2020 8:09 AM|PR Newswire|About: REGN
TARRYTOWN, N.Y. and CAMBRIDGE, Mass., March 16, 2020 /PRNewswire/ --
U.S. Phase 2/3 trial initiated and will begin enrolling patients immediately
Regeneron is leading U.S. trials, Sanofi will lead upcoming ex-U.S. trials
Regeneron Pharmaceuticals, Inc. (REGN) (NASDAQ: REGN) and Sanofi today announced they have started a clinical program evaluating Kevzara® (sarilumab) in patients hospitalized with severe COVID-19 infection.
http://www.chinaxiv.org/abs/202003.00026
http://products.sanofi.us/Kevzara/Kevzara.pdf
https://seekingalpha.com/symbol/REGN
https://seekingalpha.com/symbol/SNY
December 10, 2019 at 8:29 AM EST Back
TARRYTOWN, N.Y. and PARIS, Dec. 10, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi
Mon March 16, 2020 12:42 PM|Business Wire|About: MRNA
63 days from sequence selection to Phase 1 study dosing
mRNA-1273 is Moderna’s 10th infectious disease vaccine to begin a clinical trial
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Moderna, Inc. (MRNA)
NIAID Now | February 19, 2020
https://www.businesswire.com/news/home/20200316005666/en/
https://www.niaid.nih.gov/news-events/atomic-structure-novel-coronavirus-protein
Mon March 16, 2020 4:53 PM|PR Newswire|About: CHGCY, RHHBY
PR Newswire
INDIANAPOLIS, March 16, 2020 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY)
https://diagnostics.roche.com/
https://diagnostics.roche.com/global/en/products/params/cobas-sars-cov-2-test.html
https://diagnostics.roche.com/us/en/home.html#selectProfile
https://seekingalpha.com/symbol/RHHBY
https://seekingalpha.com/symbol/CHGCY
PUBLISHED WED, MAR 11 202012:27 PM EDTUPDATED WED, MAR 11 20208:55 PM EDTDawn Kopecki@DAWN_KOPECKIBerkeley Lovelace Jr.@BERKELEYJRWilliam Feuer@WILLFOIANoah Higgins-Dunn@HIGGINSDUNN
Thu March 12, 2020 7:00 AM|PR Newswire|About: ABBV
PR Newswire
NORTH CHICAGO, Ill., March 12, 2020 /PRNewswire/ -- AbbVie (ABBV)
https://www.abbvie.com/our-science/therapeutic-focus-areas/oncology.html
https://seekingalpha.com/symbol/ABBV
Wed March 11, 2020 1:07 PM|Canada Newswire|About: ABBV
MONTRÉAL, March 11, 2020 /CNW/ - AbbVie (ABBV),
https://seekingalpha.com/symbol/ABBV
Thu March 12, 2020 6:45 AM|PR Newswire|About: MNK
STAINES-UPON-THAMES, United Kingdom, March 12, 2020 /PRNewswire/ -- Mallinckrodt plc (MNK) (NYSE: MNK)
https://www.inomax.com/wp-content/themes/inomax-website/dist/downloads/Inomax-PI.pdf
http://www.mallinckrodt.com/about/news-and-media/news-detail/?id=26576
https://seekingalpha.com/symbol/MNK
Thu March 12, 2020 9:18 AM|GlobeNewswire|About: CYDYGlobeNewswire
VANCOUVER, Washington, March 12, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (CYDY)
https://www.cytodyn.com/pipeline/hiv
Thu March 12, 2020 8:00 AM|PR Newswire|About: LLYPR Newswire
RIDGEFIELD, Conn. and INDIANAPOLIS, March 12, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of Jardiance® (empagliflozin) to reduce the risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease, Boehringer Ingelheim and Eli Lilly and Company (LLY)
https://clinicaltrials.gov/ct2/show/NCT03594110
https://www.boehringer-ingelheim.us/
https://www.lillydiabetes.com/
https://seekingalpha.com/symbol/LLY
Mon March 9, 2020 8:45 AM|PR Newswire|About: ABBV
PR Newswire
NORTH CHICAGO, Ill., March 9, 2020 /PRNewswire/ -- AbbVie (ABBV)
https://seekingalpha.com/symbol/ABBV
https://seekingalpha.com/symbol/GILD
Tue March 10, 2020 11:32 AM|Business Wire|About: GILD
BOSTON--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD)
https://www.businesswire.com/news/home/20200310005729/en/
https://seekingalpha.com/symbol/GILD
Tue March 10, 2020 4:01 PM|PR NewswirePR Newswire
RARITAN, N.J., March 10, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson
https://clinicaltrials.gov/ct2/show/NCT02609776
DuoBody® is a registered trademark of Genmab A/S.
https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics
https://seekingalpha.com/symbol/JNJ
Basel, 11 March 2020 — Roche (SIX: RO, ROG; OTCQX: RHHBY)
https://diagnostics.roche.com/#selectProfile
Mar. 11, 2020 6:53 AM ET|About: Roche Holding Ltd ADR (RHHBY)|By: Douglas W. House, SA News Editor
https://seekingalpha.com/news/3550440-fda-oks-roche-cervical-cancer-test
https://seekingalpha.com/symbol/RHHBY
Tue March 10, 2020 2:33 PM|Business Wire|About: GILD
-- Results Presented at CROI 2020 Support Further Evaluation of Vesatolimod as Part of Investigational Curative Regimens Aimed at Achieving ART-Free Control of HIV --
BOSTON--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD)
https://www.businesswire.com/news/home/20200310005875/en/
https://clinicaltrials.gov/ct2/show/NCT02579382
Mar. 10, 2020 3:39 PM ET|About: Gilead Sciences, Inc. (GILD)|By: Douglas W. House, SA News Editor
https://seekingalpha.com/news/3550263-gileads-vesatolimod-shows-modest-effect-early-stage-hiv-study
Wed March 11, 2020 6:59 AM|Business Wire|About: BMY
Opdivo + Yervoy is the first and only dual immunotherapy approved in this setting
Approval based on CheckMate -040 trial in which Opdivo + Yervoy showed an overall response rate of 33% (16/49; 95% CI: 20-48) in this patient population1
Opdivo + Yervoy combination is now approved to treat four types of cancer
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb Company (NYSE: BMY)
https://www.businesswire.com/news/home/20200311005141/en/
Opdivo + Yervoy is the first and only dual immunotherapy approved in this setting
Approval based on CheckMate -040 trial in which Opdivo + Yervoy showed an overall response rate of 33% (16/49; 95% CI: 20-48) in this patient population1
Opdivo + Yervoy combination is now approved to treat four types of cancer
CORPORATE/FINANCIAL NEWSWEDNESDAY, MARCH 11, 2020 6:59 AM EDT
https://seekingalpha.com/symbol/BMY
Thu March 5, 2020 9:44 AM|PR Newswire|About: AGN
PR Newswire
DUBLIN, March 5, 2020 /PRNewswire/ -- Allergan plc (AGN)
https://media.allergan.com/products/durysta_pi.pdf
https://seekingalpha.com/symbol/AGN
Mar. 5, 2020 10:00 AM ET|About: Allergan plc (AGN)|By: Douglas W. House, SA News Editor
https://seekingalpha.com/news/3549041-fda-oks-allergan-eye-implant-for-glaucoma
Biocartis Announces New Immuno-Oncology Project with Bristol-Myers Squibb Aimed at Registration of Idylla™ MSI test in China
March 05, 2020 01:01 ET | Source: Biocartis NVmultilang-release
PRESS RELEASE
5 March 2020, 07:01 CET
Biocartis Announces New Immuno-Oncology Project with Bristol-Myers Squibb Aimed at Registration of Idylla™ MSI test in China
Mechelen, Belgium, 5 March 2020 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’
https://www.biocartis.com/en-US/meet-idylla/idylla-assays/idylla-msi-assay
https://seekingalpha.com/symbol/BMY
https://www.biocartis.com/en-US
Thu March 5, 2020 4:11 PM|Newsfile|About: NNVCNewsfile Corp
The Company has been working on a drug candidate to address the COVID-19 and has made significant progress in this regard
New York, New York--(Newsfile Corp. - March 5, 2020) - NanoViricides, Inc. (NNVC)
https://www.newsfilecorp.com/release/53198
http://www.nanoviricides.com/index.html
Fri March 6, 2020 7:00 AM|PR Newswire|About: ABBV
PR Newswire
NORTH CHICAGO, Ill., March 6, 2020 /PRNewswire/ -- AbbVie (ABBV)
March 6, 2020
https://seekingalpha.com/symbol/ABBV
Fri March 6, 2020 7:05 AM|Business Wire|About: ENTA
WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (ENTA),
https://seekingalpha.com/symbol/ENTA
NEWS PROVIDED BY
U.S. Food and Drug Administration
Mar 06, 2020, 18:41 ET
SHARE THIS ARTICLE
SILVER SPRING, Md., March 6, 2020 /PRNewswire/
MARCH 07, 2020Patrick Campbell
Osilodrostat. Osilodrostat, sold under the brand name Isturisa, a medication for the treatment for adults with Cushing's disease who either cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease. It is taken by mouth
https://seekingalpha.com/news/3549544-fda-oks-novartis-osilodrostat-for-adrenal-gland-disorder
Sun March 8, 2020 5:52 PM|GlobeNewswire|About: CYDY
Coronavirus Can Quickly Progress to Severe Pneumonia and Even Death Due to Immune Hyperactivity Including Acute Respiratory Distress Syndrome (ARDS); CytoDyn's Trial Focuses on Patients Who Develop Mild-To-Moderate Respiratory Illness After Contracting Coronavirus
CytoDyn Negotiating to Expedite Setup of Treatment Clinics in New York and San Francisco
VANCOUVER, Washington, March 08, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (CYDY)
https://www.cdc.gov/coronavirus/2019-ncov/index.html
https://seekingalpha.com/symbol/CYDY
The president and CEO of CytoDyn Inc. believes leronlimab will help people with moderate to severe cases of coronavirus.Author: Mike BennerPublished: 10:21 PM PDT March 9, 2020Updated: 11:06 PM PDT March 9, 2020
PORTLAND, Ore. —
Wed March 4, 2020 6:00 AM|GlobeNewswire|About: CYDY
VANCOUVER, Washington, March 04, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (CYDY)
https://www.cytodyn.com/pipeline/cancer
Basel, 4 March 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY)
https://www.nytimes.com/reuters/2020/03/04/world/europe/04reuters-roche-device.html
Wed March 4, 2020 6:45 AM|PR Newswire|About: MNKPR Newswire
STAINES-UPON-THAMES, United Kingdom, March 4, 2020 /PRNewswire/ -- Mallinckrodt plc (MNK) (NYSE: MNK)
https://www.mallinckrodt.com/investors/presentation-documents/
https://www.acthar.com/pdf/Acthar-PI.pdf
https://www.mallinckrodt.com/about/news-and-media/news-detail/?id=26546
https://www.acthar.com/patient
Tue March 3, 2020 5:50 PM|Business Wire|About: ACAD
Trofinetide is an investigational drug. It is a novel synthetic analog of the amino‐terminal tripeptide of IGF-1 designed to treat the core symptoms of Rett syndrome by potentially reducing neuroinflammation and supporting synaptic function.
https://www.businesswire.com/news/home/20200303006075/en/
https://seekingalpha.com/symbol/ACAD
http://www.neurenpharma.com/irm/content/default.aspx
https://seekingalpha.com/symbol/NURPF
Mar. 4, 2020 7:13 AM ET|About: ACADIA Pharmaceuticals... (ACAD)|By: Douglas W. House, SA News Editor
Wed March 4, 2020 5:00 AM|GlobeNewswire|About: AGN, EDIT
AGN-151587 (EDIT-101) is the first in vivo CRISPR medicine to be administered to patients
Additional patient enrollment to the BRILLIANCE Clinical Trial is ongoing
DUBLIN, Ireland and CAMBRIDGE, Mass., March 04, 2020 (GLOBE NEWSWIRE) -- Allergan plc (AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (EDIT)
Mar. 4, 2020 7:40 AM ET|About: Allergan plc (AGN)|By: Mamta Mayani, SA News Editor
Allergan (NYSE:AGN) and Editas Medicine (NASDAQ:EDIT
www.clinicaltrials.gov (NCT#03872479)
https://www.editasmedicine.com/
https://www.editasmedicine.com/gene-editing-pipeline/
https://seekingalpha.com/symbol/EDIT
https://seekingalpha.com/symbol/AGN
https://clinicaltrials.gov/ct2/show/NCT03872479?term=agn-151587&draw=2&rank=1
Thu March 5, 2020 6:00 AM|Business Wire|About: PODD
Product Innovation Award Further Validates Omnipod as a Consumer Preferred Solution
ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (PODD)
https://productoftheyearusa.com/
https://www.womansday.com/life/a30517486/product-of-the-year-2020-winners/
https://www.myomnipod.com/home
https://www.businesswire.com/news/home/20200305005044/en/
https://seekingalpha.com/symbol/PODD
Mar. 4, 2020 3:19 PM ET | About: Insulet Corporation (PODD)
Mon March 2, 2020 11:13 AM|GlobeNewswire|About: GWPH
GlobeNewswire
CARLSBAD, Calif., March 02, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (GWPRF) (NASDAQ: GWPH, GW, the Company or the Group)
https://seekingalpha.com/symbol/GWPH
Mon March 2, 2020 8:30 AM|PR Newswire
PR Newswire
RARITAN, N.J., March 2, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson
https://clinicaltrials.gov/ct2/show/NCT03252847?term=rpgr&draw=2&rank=1
https://clinicaltrials.gov/ct2/show/NCT03252847?term=rpgr&draw=2&rank=1
https://seekingalpha.com/symbol/JNJ
Mar. 2, 2020 11:32 AM ET|About: Johnson & Johnson (JNJ)|By: Douglas W. House, SA News Editor
Published: Mar 2, 2020 10:27 a.m. ET
Bloomberg NewsBloombergMarch 1, 2020
https://finance.yahoo.com/news/chinese-biotech-censured-false-claim-040207427.html
https://clinicaltrials.gov/ct2/show/NCT04257656?term=remdesivir&draw=2&rank=1
January 31, 2020
DOI: 10.1056/NEJMoa2001191
Chinese Translation 中文翻译
https://www.nejm.org/doi/10.1056/NEJMoa2001191
February 26, 2020
-- U.S. FDA Grants Investigational New Drug Authorization to Study Remdesivir for the Treatment of COVID-19 --
FOSTER CITY, Calif.--(BUSINESS WIRE)--Feb. 26, 2020-- Gilead Sciences, Inc. (Nasdaq: GILD)
March 02, 2020
https://seekingalpha.com/symbol/SNY
Mar. 2, 2020 12:51 PM ET|About: Sanofi (SNY)|By: Douglas W. House, SA News Editor
https://seekingalpha.com/news/3547590-fda-oks-sanofi-drug-for-previously-treated-multiple-myeloma
What is POMALYST® (pomalidomide)?
POMALYST® (pomalidomide) is a prescription medicine, taken along with the medicine dexamethasone, used to treat people with multiple myeloma who have previously received at least 2 medicines to treat multiple myeloma, including a proteasome inhibitor and lenalidomide, and whose disease has become worse during treatment or within 60 days of finishing the last treatment. It is not known if POMALYST is safe and effective in children.
https://seekingalpha.com/symbol/BMY
Mon March 2, 2020 1:51 PM|GlobeNewswire|About: SNY
FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma
PARIS – March 2, 2020 – The U.S. Food and Drug Administration (FDA) has approved Sarclisa® (isatuximab-irfc) in combination with pomalidomide and dexamethasone (pom-dex) for the treatment of adults with relapsed refractory multiple myeloma (RRMM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. Sarclisa is expected to be available to patients in the U.S. shortly.
Tue March 3, 2020 6:00 AM|Canada Newswire
DORVAL, QC, March 3, 2020 /CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis)
https://seekingalpha.com/symbol/NVS
.
Tue March 3, 2020 1:00 AM|Business Wire|About: RHHBY
– There are currently no FDA-approved treatments for unclassifiable ILD (uILD), a debilitating, severe respiratory condition –
– The designation is based on results from a Phase II trial, which suggested Esbriet slowed disease progression in patients with uILD at 24 weeks –
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY)
https://www.businesswire.com/news/home/20200302006109/en/
https://seekingalpha.com/symbol/RHHBY
Monday, Mar 2, 2020
South San Francisco, CA -- March 2, 2020 --
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY)
https://www.gene.com/media/press-releases/14840/2020-03-02/fda-grants-breakthrough-therapy-designat
Thu March 5, 2020 6:45 AM|PR Newswire|About: MNKPR Newswire
STAINES-UPON-THAMES, United Kingdom, March 5, 2020 /PRNewswire/ -- Mallinckrodt plc (MNK) (NYSE: MNK),
Mon March 2, 2020 6:45 AM|PR Newswire|About: MNK
PR Newswire
STAINES-UPON-THAMES, United Kingdom, March 2, 2020 /PRNewswire/ -- Mallinckrodt plc (MNK) (NYSE: MNK)
https://seekingalpha.com/symbol/MNK
Mon March 2, 2020 4:00 AM|Business Wire|About: CLVS
https://www.clovisoncology.com/
https://www.businesswire.com/news/home/20200302005009/en/
https://clovisoncology.com/pipeline/rucaparib/
Mon March 2, 2020 6:30 AM|Business Wire|About: MRK
Data from Pivotal Phase 3 KEYNOTE-204 Study to be Presented at an Upcoming Medical Meeting and Submitted to Regulatory Authorities
KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (MRK), known as MSD outside the United States and Canada,
https://clinicaltrials.gov/ct2/show/NCT02684292
https://www.merck.com/index.html
https://www.businesswire.com/news/home/20200302005320/en/
Mar. 2, 2020 8:23 AM ET|About: Merck & Co., Inc. (MRK)|By: Douglas W. House, SA News Editor
https://seekingalpha.com/symbol/MRK
Mon March 2, 2020 6:45 AM|PR Newswire|About: LLY, PFE
NEW YORK and INDIANAPOLIS, March 2, 2020 /PRNewswire/ -- Pfizer Inc. (PFE) and Eli Lilly and Company (LLY)
Tanezumab is an investigational monoclonal antibody that works by selectively targeting, binding to and inhibiting NGF. NGF levels increase in the body as a result of injury, inflammation or in chronic pain states.
https://seekingalpha.com/symbol/PFE
https://seekingalpha.com/symbol/LLY
Mon March 2, 2020 8:00 AM|Business Wire|About: TAK
– If Approved by the European Medicines Agency, ALUNBRIG Would Become an Important First-Line Treatment Option for ALK+ NSCLC Patients –
– Positive Opinion is Based on Data from Phase 3 ALTA-1L Trial, in which ALUNBRIG Demonstrated Superiority in both Overall and Intracranial Efficacy Compared to Crizotinib –
CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TKPHF) (TSE:4502/NYSE:TAK)
https://www.businesswire.com/news/home/20200302005068/en/
March 02, 2020
– Gilead Gains Forty Seven’s Investigational Immuno-Oncology Therapy in Multiple Clinical Studies for Diseases Including Myelodysplastic Syndrome, Acute Myeloid Leukemia and Diffuse Large B-Cell Lymphoma –
– Transaction Supports Gilead’s Strategic Focus in Oncology and Gives Access to Potential New First-in-Class Program and Innovative Pipeline –
FOSTER CITY, Calif. & MENLO PARK, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Forty Seven, Inc. (Nasdaq: FTSV)
https://www.fortyseveninc.com/
https://www.fortyseveninc.com/science
https://seekingalpha.com/symbol/GILD
https://seekingalpha.com/symbol/FTSV
Mar. 2, 2020 7:38 AM ET|About: Forty Seven, Inc. (FTSV)|By: Douglas W. House, SA News Editor
https://seekingalpha.com/news/3547352-gilead-takes-out-forty-seven-for-4_9b
Thu February 27, 2020 7:14 AM|GlobeNewswire|About: BGNE, SWTX
-- Phase 1 Study Initiated in Australia with IND Cleared to Expand Study to the U.S.--
-- Industry-Leading Scientific Advisory Board Formed to Support Advancement of BGB-3245 --
CAMBRIDGE, Mass. and BEIJING and STAMFORD, Conn., Feb. 27, 2020 (GLOBE NEWSWIRE) -- MapKure, LLC, a clinical-stage company developing precision medicines for patients with life-threatening diseases, together with BeiGene, Ltd. (BGNE) and SpringWorks Therapeutics, Inc. (SWTX), who are joint owners of MapKure
https://clinicaltrials.gov/ct2/show/NCT04249843?term=BGB-3245&draw=2&rank=1#wrapper
https://www.beigene.com/science-and-product-portfolio/pipeline
https://www.springworkstx.com/
https://www.springworkstx.com/pipeline/
https://seekingalpha.com/symbol/BGNE
https://seekingalpha.com/symbol/SWTX
http://ir.beigene.com/static-files/ac21f420-ebe7-4627-a9c2-c38bd7940b8d
Thu February 27, 2020 6:45 AM|PR Newswire|About: MNK
PR Newswire
STAINES-UPON-THAMES, United Kingdom, Feb. 27, 2020 /PRNewswire/ -- Mallinckrodt plc (MNK) (NYSE: MNK)
https://www.acthar.com/pdf/Acthar-PI.pdf
http://www.mallinckrodt.com/about/news-and-media/news-detail/?id=26516
https://seekingalpha.com/symbol/MNK
Thu February 27, 2020 3:30 PM|GlobeNewswire|About: SRNE
SAN DIEGO, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (SRNE)
https://sorrentotherapeutics.com/pipeline/
More information on this trial can be found at www.clinicaltrials.gov (NCT03226574).
https://clinicaltrials.gov/ct2/show/NCT03226574?term=NCT03226574&draw=2&rank=1
https://sorrentotherapeutics.com/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC398431/
https://seekingalpha.com/symbol/SRNE
Feb. 28, 2020 4:43 PM ET|About: Pfizer Inc. (PFE)|By: Jason Aycock, SA News Editor
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/211733Orig1s000ltr.pdf
Fri February 28, 2020 6:53 PM|PR Newswire|About: ABBV
PR Newswire
NORTH CHICAGO, Ill., Feb. 28, 2020 /PRNewswire/ -- AbbVie (ABBV)
https://www.abbvie.com/our-science/therapeutic-focus-areas/oncology.html
https://seekingalpha.com/symbol/ABBV
Feb. 28, 2020 7:10 PM ET|About: AbbVie Inc. (ABBV)|By: Jason Aycock, SA News Editor
https://seekingalpha.com/news/3547230-abbvie-venetoclax-combo-trial-misses-endpoint
Mon March 2, 2020 6:45 AM|Business Wire|About: MRK
KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (MRK), known as MSD outside the United States and Canada,
https://www.croiconference.org/
https://www.merck.com/index.html
https://www.businesswire.com/news/home/20200302005284/en/
https://seekingalpha.com/symbol/MRK
Tue February 25, 2020 4:06 PM|Business Wire|About: EXEL
– Analysis for the co-primary endpoint of objective response rate and an interim analysis of progression-free survival expected in the second half of 2020 –
ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (EXEL) (NASDAQ: EXEL)
https://www.businesswire.com/news/home/20200225005987/en/
https://clinicaltrials.gov/ct2/show/NCT03690388
https://cabometyx.com/downloads/CABOMETYXUSPI.pdf
https://www.businesswire.com/news/home/20200225005987/en/
https://seekingalpha.com/symbol/EXEL
Wed February 26, 2020 8:30 AM|GlobeNewswire|About: SLS
- Final analysis shows statistically significant median overall survival of 21 months in patients who received GPS compared to previously reported 5.4 months in the control arm (p-value < 0.02) -
- Data provides additional support for ongoing pivotal Phase 3 REGAL study of GPS in patients with AML -
NEW YORK, Feb. 26, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (SLS)
https://www.clinicaltrials.gov/ct2/show/NCT04229979?term=galinpepimut-S&draw=2&rank=3
https://www.sellaslifesciences.com/Home/default.aspx
https://seekingalpha.com/symbol/SLS
Gilead Sciences Inc. has been granted three patents in China for its antiviral drug remdesivir, which has been undergoing clinical tests to determine if it can effectively treat the coronavirus, He Zhimin, deputy director of the National Intellectual Property Administration said (link in Chinese) at a press conference on Tuesday.
The U.S. drugmaker has applied for eight patents for the drug and the other five are still being reviewed, according to He. The eight patents cover areas including compounds, manufacturing methods and drug usage.
http://www.china.org.cn/china/2020-02/26/content_75745874.htm
Source: Xinhua| 2020-02-25 19:05:41|Editor: huaxia
BEIJING, Feb. 25 (Xinhua)
Wed February 26, 2020 5:30 PM|GlobeNewswire|About: ESPR
- NEXLIZET Lowered LDL-C by 38 Percent Compared to Placebo when Added on to Maximally Tolerated Statins -
- First Non-Statin, LDL-Cholesterol Lowering Combination Medicine Ever Approved -
- Esperion’s Second Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine Approved in the U.S. Following NEXLETOL™ (bempedoic acid) Tablet Approval on February 21, 2020 -
- Further Underscores Esperion’s Commitment to Patient Affordability -
- Conference Call and Webcast on Thursday, February 27 at 8:00 a.m. Eastern Time -
ANN ARBOR, Mich., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR)
Feb 26, 2020
https://pi.esperion.com/nexlizet/nexlizet-pi.pdf
NEXLETOL™ (bempedoic acid) Tablet
https://seekingalpha.com/symbol/ESPR
02/26/2020Download PDFRegulatory submission based on the positive Phase 3 RELAY study of CYRAMZA in combination with erlotinib for the first-line treatment of adult patients with metastatic non-small cell lung cancer with activating EGFR mutations
INDIANAPOLIS, Feb. 26, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY)
VOLUME 20, ISSUE 12, P1655-1669, DECEMBER 01, 2019
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30634-5/fulltext
http://uspl.lilly.com/cyramza/cyramza.html
https://www.lillyoncology.com/
https://clinicaltrials.gov/ct2/show/NCT02411448
Wed February 26, 2020 5:00 PM|Business Wire|About: GILD
-- U.S. FDA Grants Investigational New Drug Authorization to Study Remdesivir for the Treatment of COVID-19 --
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD)
https://www.gilead.com/purpose/advancing-global-health/covid-19
https://www.businesswire.com/news/home/20200226005955/en/
Remdesivir is an investigational nucleotide analog with broad-spectrum antiviral activity both in vitro and in vivo in animal models against multiple emerging viral pathogens including Ebola, Marburg, MERS and SARS.
https://seekingalpha.com/symbol/GILD
Fri February 21, 2020 6:59 AM|Business Wire|About: BMY
First approval of Opdivo for treatment of advanced esophageal cancer
First Immuno-Oncology treatment option approved for patients with esophageal cancer in Japan
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (BMY)
https://www.businesswire.com/news/home/20200221005172/en/
Fri February 21, 2020 7:50 PM|PR Newswire|About: LLYPR Newswire
INDIANAPOLIS, Feb. 21, 2020 /PRNewswire/
http://pi.lilly.com/us/trulicity-uspi.pdf
https://www.lillydiabetes.com/
Feb. 21, 2020, 2:30 PM
Feb. 21, 2020 3:08 PM ET|About: Esperion Therapeutics,... (ESPR)|By: Douglas W. House, SA News Editor
https://seekingalpha.com/news/3544573-fda-oks-esperions-cholesterol-med-nexletol
https://seekingalpha.com/symbol/ESPR
https://pi.esperion.com/nexletol/nexletol-pi.pdf
https://www.esperion.com/science/bempedoic-acid/
Fri February 21, 2020 4:38 PM|GlobeNewswire|About: ESPR
– First Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine Approved in the U.S. in Nearly 20 Years for Indicated Patients –
– NEXLETOL Lowers LDL-Cholesterol with a First-in-Class Mechanism –
– Fills an Unmet Need for Affordable Medicines for Millions of Patients with ASCVD or HeFH –
– NEXLETOL will be Commercially Available in the U.S. March 30, 2020 –
– Conference Call and Webcast on Monday, February 24 at 8:00 a.m. Eastern Time –
ANN ARBOR, Mich., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Esperion (ESPR)
Fosun Kite’s New Drug Application (NDA) Filing for Axicabtagene Ciloleucel Accepted for Review by China NMPA
(24 February, 2020, Shanghai) Today, Fosun Kite Biotechnology(“Fosun Kite”) based in Shanghai, a company invested by Shanghai Fosun Pharmaceutical (Group) Co., Ltd (“Fosun Pharma” or “Group”; Stock Code: 600196.SH, 02196.HK),
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* Announcement in Relation to Acceptance of New Drug Application Filing from Fosun Kite Biotechnology Co., Ltd.*
https://www1.hkexnews.hk/listedco/listconews/sehk/2020/0224/2020022400822.pdf
Feb. 24, 2020 7:46 AM ET|About: Gilead Sciences, Inc. (GILD)|By: Liz Kiesche, SA News Editor
https://seekingalpha.com/symbol/GILD
Mon February 24, 2020 8:00 AM|Business Wire|About: TAK
– ALUNBRIG has Potential to Expand its Indication in ALK+ Metastatic Non-Small Cell Lung Cancer –
– Prescription Drug User Fee Act (PDUFA) Target Action Date Set for June 23, 2020 –
CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TKPHF) (TSE:4502/NYSE:TAK)
https://www.businesswire.com/news/home/20200224005128/en/
https://seekingalpha.com/symbol/TAK
Mon February 24, 2020 7:00 AM|GlobeNewswire|About: AVXL
Published in Journal of Neuroimmunology, Results Highlight ANAVEX®2-73 (blarcamesine) Shown to Protect and Repair Myelin Forming Cells
ANAVEX®2-73 (blarcamesine) Provides optimal Protection of Oligodendroglia against Glutamate Toxicity
NEW YORK, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (AVXL) (“Anavex” or the “Company”) (Nasdaq: AVXL)
https://www.sciencedirect.com/science/article/abs/pii/S0165572819305831
https://seekingalpha.com/symbol/AVXL
Tue February 18, 2020 7:17 PM|Business Wire|About: MRK
KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (MRK)
https://www.merck.com/clinical-trials/index.html
https://www.merck.com/index.html
https://www.businesswire.com/news/home/20200218006165/en/
https://seekingalpha.com/symbol/MRK
Wed February 19, 2020 7:30 AM|Business Wire|About: INCY
For more information about the TRuE-AD studies, please visit http://clinicaltrials.gov/ct2/show/NCT03745638 and http://clinicaltrials.gov/ct2/show/NCT03745651.
About Ruxolitinib Cream
Ruxolitinib cream is a proprietary formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib that has been designed for topical application. Ruxolitinib cream is currently in Phase 3 development for the treatment of patients with mild-to-moderate atopic dermatitis (TRuE-AD) and for the treatment of adolescents and adults with vitiligo (TRuE-V). Incyte has worldwide rights for the development and commercialization of ruxolitinib cream.
https://www.businesswire.com/news/home/20200219005204/en/
https://seekingalpha.com/symbol/INCY
Wed February 19, 2020 8:12 AM|Business Wire|About: ALPMY, SGEN
- Breakthrough Therapy Designation Based on Initial Results from Phase 1b/2 EV-103 Clinical Trial -
BOTHELL, Wash. & TOKYO--(BUSINESS WIRE)-- Seattle Genetics, Inc. (SGEN) (Nasdaq:SGEN) and Astellas Pharma Inc. (ALPMF) (TSE: 4503
https://www.seattlegenetics.com/
https://www.businesswire.com/news/home/20200219005512/en/
https://seekingalpha.com/symbol/ALPMY
https://seekingalpha.com/symbol/SGEN
Thu February 20, 2020 8:00 AM|PR Newswire|About: ABT
PR Newswire
MADRID, Feb. 20, 2020 /PRNewswire/ -- Abbott (ABT)
https://seekingalpha.com/symbol/ABT
Thu February 20, 2020 7:00 AM|GlobeNewswire|About: AXSM
NEW YORK, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (AXSM)
https://axsome.com/axs-pipeline/about-axs-07/
Thu February 20, 2020 4:05 PM|PR Newswire|About: BMRN
PR Newswire
SAN RAFAEL, Calif., Feb. 20, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (BMRN)
https://www.biomarin.com/products/pipeline/bmn-270/
Feb 17, 2020
Basel, February 17, 2020
https://seekingalpha.com/symbol/NVS
Tue February 18, 2020 6:45 AM|Business Wire|About: PFE
—VYNDAQEL is the only EC-approved medicine proven to reduce mortality and frequency of cardiovascular-related hospitalizations in adults with wild-type or hereditary ATTR-CM—
—VYNDAQEL is the first approved medicine in the EU to treat both ATTR-CM and stage 1 symptomatic transthyretin amyloid polyneuropathy (ATTR-PN)—
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (PFE)
http://labeling.pfizer.com/ShowLabeling.aspx?id=11685
https://www.businesswire.com/news/home/20200218005225/en/
https://seekingalpha.com/symbol/PFE
Tue February 18, 2020 7:45 AM|PR Newswire|About: ABT
PR Newswire
ABBOTT PARK, Ill., Feb. 18, 2020 /PRNewswire/ -- Abbott (ABT)
https://seekingalpha.com/symbol/ABT
Tue February 18, 2020 8:00 AM|Business Wire|About: HZNP
-- Oral granules in packets provide an additional, tear-open option for people living with cystinosis --
DUBLIN--(BUSINESS WIRE)-- Horizon Therapeutics plc (Nasdaq: HZNP)
https://www.businesswire.com/news/home/20200218005293/en/
https://www.hzndocs.com/PROCYSBI-Prescribing-Information.pdf
https://www.horizontherapeutics.com/
https://seekingalpha.com/symbol/HZNP
Wed February 19, 2020 1:00 AM|Business Wire|About: RHHBY
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY
https://www.businesswire.com/news/home/20200218006211/en/
https://www.gene.com/topics/cancer-immunotherapy
Basel, 14 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY)
Feb. 14, 2020 7:00 AM ET|About: Roche Holding AG (RHHBY)|By: Douglas W. House, SA News Editor
https://seekingalpha.com/news/3542132-roches-tecentriq-okd-in-china-for-first-line-lung-cancer
https://seekingalpha.com/symbol/RHHBY
https://www.gene.com/medical-professionals/pipeline
Fri February 14, 2020 2:00 AM|PR Newswire
PR Newswire
VIENNA, Feb. 14, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson
http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf
https://clinicaltrials.gov/ct2/show/NCT03107793
Crohn’s disease is a chronic inflammatory condition of the gastrointestinal tract. Understanding Crohn’s disease can help you and your loved ones navigate the uncertainty that comes with a new diagnosis.
https://www.crohnscolitisfoundation.org/what-is-crohns-disease/overview
Feb 14, 2020Austria
Fri February 14, 2020 8:30 AM|GlobeNewswire|About: SLSGlobeNewswire
NEW YORK, Feb. 14, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (SLS)
https://www.sellaslifesciences.com/Home/default.aspx
https://seekingalpha.com/symbol/SLS
Fri February 14, 2020 11:20 AM|Business Wire|About: MRK
Democratic Republic of the Congo One of the First African Countries to Register ERVEBO
KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (MRK)
https://www.businesswire.com/news/home/20200214005376/en/
https://www.merck.com/index.html
https://www.fda.gov/vaccines-blood-biologics/ervebo
Sat February 15, 2020 2:30 PM|Business Wire|About: BMY
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (BMY) (NYSE: BMY)
https://www.businesswire.com/news/home/20200215005014/en/
https://seekingalpha.com/symbol/BMY
Feb 16, 2020 11:16 AM
By Jia Tianqiong, Di Ning, Lu Yutong and Flynn Murphy
The remdesivir trials are backed by Capital Medical University in collaboration with the Chinese Academy of Medical Sciences.
Wed February 12, 2020 7:00 AM|Canada Newswire|About: AMGN
Addition of OTEZLA Strengthens Amgen (AMGN)'s Long-Standing Expertise in Inflammation
MISSISSAUGA, ON, Feb. 12, 2020 /CNW/ - Today, Amgen Canada Inc.
https://seekingalpha.com/symbol/AMGN
Wed February 12, 2020 8:30 AM|GlobeNewswire|About: VIR
SAN FRANCISCO, Feb. 12, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (VIR)
https://seekingalpha.com/symbol/VIR
Wed February 12, 2020 6:45 AM|Business Wire|About: MRK
KEYNOTE-355 is a randomized, two-part, Phase 3 trial (ClinicalTrials.gov, NCT02819518) evaluating KEYTRUDA in combination with one of three different chemotherapies (investigator’s choice of either nab-paclitaxel, paclitaxel or gemcitabine/carboplatin)
https://clinicaltrials.gov/ct2/show/NCT02819518
https://www.businesswire.com/news/home/20200212005254/en/
https://www.merck.com/clinical-trials/index.html
Thu February 13, 2020 6:59 AM|Business Wire|About: BMY
https://www.businesswire.com/news/home/20200213005238/en/
https://seekingalpha.com/symbol/BMY
Thu February 13, 2020 8:00 AM|Business Wire|About: SGEN
https://www.nejm.org/doi/full/10.1056/NEJMoa1914609?query=featured_home
https://clinicaltrials.gov/ct2/show/NCT03975647?term=tucatinib&draw=3
https://www.clinicaltrials.gov/ct2/show/NCT03043313?term=MOUNTAINEER&draw=2&rank=1
https://www.seattlegenetics.com/
https://www.businesswire.com/news/home/20200213005275/en/
Herceptin (trastuzumab)
https://seekingalpha.com/symbol/SGEN
Thu February 13, 2020 8:00 AM|GlobeNewswire|About: ADXS
Median overall survival of 16.4 months for advanced prostate cancer patients with visceral metastases treated with ADXS-PSA in combination with KEYTRUDA® compared to an estimated 11 months with Standard of Care
Median overall survival of 33.7 months in all patients treated with ADXS-PSA in combination with KEYTRUDA®
PRINCETON, N.J., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (ADXS)
https://advaxis.com/clinical-trials/
About KEYNOTE-046
KEYNOTE-046 (NCT02325557) was a Phase 1/2 open-label, multicenter, dose-determination and expansion trial that evaluates the safety, tolerability and preliminary clinical activity of ADXS-PSA as monotherapy (Part A; n=14 [13 treated]), and in combination with KEYTRUDA® (Part B; n= 37) in heavily pretreated patients with progressive and refractory mCRPC.
https://seekingalpha.com/symbol/ADXS
Tue February 11, 2020 8:00 AM|PR Newswire|About: ALPMY, PFE
TOKYO and NEW YORK, Feb. 11, 2020 /PRNewswire/ -- Astellas Pharma Inc. (ALPMF) (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Pfizer Inc. (PFE)
https://clinicaltrials.gov/ct2/show/NCT02003924
https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf
https://seekingalpha.com/symbol/MDVN
https://seekingalpha.com/symbol/ALPMY
https://seekingalpha.com/symbol/PFE
Tue February 11, 2020 8:00 AM|GlobeNewswire|About: PHAS
PB2452 granted PRIME Designation by the European Medicines Agency
PhaseBio receives written scientific advice confirming PB2452 clinical development plan
In Phase 1 and Phase 2a clinical trials, PB2452 provided immediate and sustained reversal of the antiplatelet effects of ticagrelor
MALVERN, Pa. and SAN DIEGO, Feb. 11, 2020 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc (PHAS). (Nasdaq: PHAS)
https://phasebio.com/pipeline/
The European Medicines Agency has granted PRIME status to PhaseBio Pharmaceuticals' (PHAS -2.1%) PB2452 as a reversal agent of AstraZeneca's (AZN) anticoagulant Brilinta (ticagrelor).
https://seekingalpha.com/symbol/PHAS